We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > BridgeBio

News List

FDA approves Nulibry to treat Molybdenum Cofactor Deficiency Type A pharmatimes
March 02, 2021
The US Food and Drug Administration (FDA) has approved BridgeBio Pharma and Origin Biosciences’ Nulibry (fosdenopterin), making it the first treatment to be authorised to reduce the risk of mortality in patients with molybdenum cofactor deficiency ...
BridgeBio Pharma LLC Signs Joint Collaboration Agreement with Cincinnati Children's to Accelerate Development of Genetic Disease Therapeutics pharmafocusasia
November 13, 2018
"BridgeBio is privileged to partner with leading experts at Cincinnati Children's, an institution whose impact on science and patients we admire. We hope we can help advance the mission by partnering to move therapies forward to patients," said Neil Kumar
BridgeBio Launches CoA Therapeutics contractpharma
June 19, 2018
BridgeBio Pharma announced the launch of CoA Therapeutics, a biopharmaceutical company developing novel small-molecules designed to increase Coenzyme-A (CoA) levels in genetic disorders where CoA deficiency is implicated.
BridgeBio Launches QED Therapeutics With $65M and an Abandoned Novartis Cancer Program biospace
January 31, 2018
Palo Alto, Calif.-based BridgeBio Pharma is launching a new spinout to develop a recently-abandoned Novartis cancer treatment now in its possession.